[en] Idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF) are characterised by an irreversible progression of pulmonary fibrosis and functional lung decline. Current antifibrotic therapies (nintedanib and pirfenidone for IPF and nintedanib for PPF) can reduce disease progression but not halt or reverse it. PPF and IPF share common pathophysiological pathways that need to be further elucidated for the development of novel therapeutic strategies. The educational aim of this review is to explain the pathogenic pathways that have led to the discovery of new therapeutic agents and their favourable implementation in phase 2 and 3 studies. This includes phosphodiesterase 4 inhibitors, αvβ6 and αvβ1 integrin inhibitors, lymphosphatidic acid antagonists, inhaled treprostinil, hedgehog inhibitors, tyrosine kinase inhibitors and angiotensin type 2 receptor agonists. The aim is also to better understand current therapeutic challenges and future perspectives, including cellular therapies, exosomes and their cargoes, as well as the integration of transcriptomics and proteomics, plus gene therapy.
Disciplines :
Cardiovascular & respiratory systems
Author, co-author :
DENIS, Anna ; Centre Hospitalier Universitaire de Liège - CHU > > Service de pneumologie - allergologie ; Both authors contributed equally
Tsiri, Panagiota; Department of Pulmonology, University Hospital of Patras, Patras, Greece ; Both authors contributed equally
Guiot, Julien ; Université de Liège - ULiège > Département des sciences cliniques > Pneumologie - Allergologie ; Both authors contributed equally
Tzouvelekis, Argyris; Department of Pulmonology, University Hospital of Patras, Patras, Greece ; Both authors contributed equally
Language :
English
Title :
A new era in the treatment of progressive fibrosing interstitial lung diseases.
Raghu G, Remy-Jardin M, Richeldi L, et al. Idiopathic pulmonary fibrosis (an update) and progressive pulmonary fibrosis in adults: an Official ATS/ERS/JRS/ALAT Clinical Practice Guideline. Am J Respir Crit Care Med 2022; 205: e18–e47.
Maher TM, Bendstrup E, Dron L, et al. Global incidence and prevalence of idiopathic pulmonary fibrosis. Respir Res 2021; 22: 197.
Ley B, Collard HR, King TE Jr. Clinical course and prediction of survival in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2011; 183: 431–440.
Raghu G, Rochwerg B, Zhang Y, et al. An official ATS/ERS/JRS/ALAT Clinical Practice Guideline: treatment of idiopathic pulmonary fibrosis. An Update of the 2011 Clinical Practice Guideline. Am J Respir Crit Care Med 2015; 192: e3–e19.
Chianese M, Screm G, Salton F, et al. Pirfenidone and nintedanib in pulmonary fibrosis: lights and shadows. Pharmaceuticals 2024; 17: 709.
Richeldi L, du Bois RM, Raghu G, et al. Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis. N Engl J Med 2014; 370: 2071–2082.
Noble PW, Albera C, Bradford WZ, et al. Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): two randomised trials. Lancet 2011; 377: 1760–1769.
King TE Jr, Bradford WZ, Castro-Bernardini S, et al. A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis. N Engl J Med 2014; 370: 2083–2092.
Bonella F, Cottin V, Valenzuela C, et al. Meta-analysis of effect of nintedanib on reducing FVC decline across interstitial lung diseases. Adv Ther 2022; 39: 3392–3402.
Petnak T, Lertjitbanjong P, Thongprayoon C, et al. Impact of antifibrotic therapy on mortality and acute exacerbation in idiopathic pulmonary fibrosis: a systematic review and meta-analysis. Chest 2021; 160: 1751–1763.
Flaherty KR, Wells AU, Cottin V, et al. Nintedanib in progressive fibrosing interstitial lung diseases. N Engl J Med 2019; 381: 1718–1727.
Distler O, Highland KB, Gahlemann M, et al. Nintedanib for systemic sclerosis-associated interstitial lung disease. N Engl J Med 2019; 380: 2518–2528.
Wells AU, Flaherty KR, Brown KK, et al. Nintedanib in patients with progressive fibrosing interstitial lung diseases-subgroup analyses by interstitial lung disease diagnosis in the INBUILD trial: a randomised, double-blind, placebo-controlled, parallel-group trial. Lancet Respir Med 2020; 8: 453–460.
Raman L, Stewart I, Barratt SL, et al. Nintedanib for non-IPF progressive pulmonary fibrosis: 12-month outcome data from a real-world multicentre observational study. ERJ Open Res 2023; 9: 00423-2022.
Ghazipura M, Mammen MJ, Bissell BD, et al. Pirfenidone in progressive pulmonary fibrosis: a systematic review and meta-analysis. Ann Am Thorac Soc 2022; 19: 1030–1039.
Behr J, Prasse A, Kreuter M, et al. Pirfenidone in patients with progressive fibrotic interstitial lung diseases other than idiopathic pulmonary fibrosis (RELIEF): a double-blind, randomised, placebo-controlled, phase (2b). trial. Lancet Respir Med 2021; 9: 476–486.
Maher TM, Corte TJ, Fischer A, et al. Pirfenidone in patients with unclassifiable progressive fibrosing interstitial lung disease: a double-blind, randomised, placebo-controlled, phase 2 trial. Lancet Respir Med 2020; 8: 147–157.
West A, Chaudhuri N, Barczyk A, et al. Inhaled pirfenidone solution (AP01) for IPF: a randomised, open-label, dose-response trial. Thorax 2023; 78: 882–889.
Spagnolo P, Cottin V. Genetics of idiopathic pulmonary fibrosis: from mechanistic pathways to personalised medicine. J Med Genet 2017; 54: 93–99.
Saha P, Talwar P. Idiopathic pulmonary fibrosis (IPF): disease pathophysiology, targets, and potential therapeutic interventions. Mol Cell Biochem 2024; 479: 2181–2194.
Adegunsoye A, Kropski JA, Behr J, et al. Genetics and genomics of pulmonary fibrosis: charting the molecular landscape and shaping precision medicine. Am J Respir Crit Care Med 2024; 210: 401–423.
Rajan SK, Cottin V, Dhar R, et al. Progressive pulmonary fibrosis: an expert group consensus statement. Eur Respir J 2023; 61: 2103187.
Zaman T, Lee JS. Risk factors for the development of idiopathic pulmonary fibrosis: a review. Curr Pulmonol Rep 2018; 7: 118–125.
Frangogiannis N. Transforming growth factor-β in tissue fibrosis. J Exp Med 2020; 217: e20190103.
Lancaster L, Cottin V, Ramaswamy M, et al. Bexotegrast in patients with idiopathic pulmonary fibrosis: the INTEGRIS-IPF clinical trial. Am J Respir Crit Care Med 2024; 210: 424–434.
Decaris ML, Schaub JR, Chen C, et al. Dual inhibition of α(v)β(6) and α(v)β(1) reduces fibrogenesis in lung tissue explants from patients with IPF. Respir Res 2021; 22: 265.
Maher TM, Evans IC, Bottoms SE, et al. Diminished prostaglandin E2 contributes to the apoptosis paradox in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2010; 182: 73–82.
Selige J, Hatzelmann A, Dunkern T. The differential impact of PDE4 subtypes in human lung fibroblasts on cytokine-induced proliferation and myofibroblast conversion. J Cell Physiol 2011; 226: 1970–1980.
Matsuhira T, Nishiyama O, Tabata Y, et al. A novel phosphodiesterase 4 inhibitor, AA6216, reduces macrophage activity and fibrosis in the lung. Eur J Pharmacol 2020; 885: 173508.
Richeldi L, Azuma A, Cottin V, et al. Trial of a preferential phosphodiesterase 4B inhibitor for idiopathic pulmonary fibrosis. N Engl J Med 2022; 386: 2178–2187.
Richeldi L, Azuma A, Cottin V, et al. Design of a phase III, double-blind, randomised, placebo-controlled trial of BI 1015550 in patients with idiopathic pulmonary fibrosis (FIBRONEER-IPF). BMJ Open Respir Res 2023; 10: e001563.
Maher TM, Assassi S, Azuma A, et al. Design of a phase III, double-blind, randomised, placebo-controlled trial of BI 1015550 in patients with progressive pulmonary fibrosis (FIBRONEER-ILD). BMJ Open Respir Res 2023; 10: e001580.
Chun J, Hla T, Lynch KR, et al. International Union of Basic and Clinical Pharmacology. LXXVIII. Lysophospholipid receptor nomenclature. Pharmacol Rev 2010; 62: 579–587.
Oikonomou N, Mouratis MA, Tzouvelekis A, et al. Pulmonary autotaxin expression contributes to the pathogenesis of pulmonary fibrosis. Am J Respir Cell Mol Biol 2012; 47: 566–574.
Shea BS, Tager AM. Role of the lysophospholipid mediators lysophosphatidic acid and sphingosine 1-phosphate in lung fibrosis. Proc Am Thorac Soc 2012; 9: 102–110.
Tager AM, LaCamera P, Shea BS, et al. The lysophosphatidic acid receptor LPA1 links pulmonary fibrosis to lung injury by mediating fibroblast recruitment and vascular leak. Nat Med 2008; 14: 45–54.
Montesi SB, Mathai SK, Brenner LN, et al. Docosatetraenoyl LPA is elevated in exhaled breath condensate in idiopathic pulmonary fibrosis. BMC Pulm Med 2014; 14: 5.
Maher TM, Ford P, Brown KK, et al. Ziritaxestat, a novel autotaxin inhibitor, and lung function in idiopathic pulmonary fibrosis: the ISABELA 1 and 2 randomized clinical trials. JAMA 2023; 329: 1567–1578.
Corte TJ, Behr J, Cottin V, et al. Efficacy and safety of admilparant, an LPA(1) antagonist in pulmonary fibrosis: a phase 2 randomized clinical trial. Am J Respir Crit Care Med 2024; 211: 230–238.
Kolb M, Orfanos SE, Lambers C, et al. The antifibrotic effects of inhaled treprostinil: an emerging option for ILD. Adv Ther 2022; 39: 3881–3895.
Ali FY, Egan K, FitzGerald GA, et al. Role of prostacyclin versus peroxisome proliferator-activated receptor beta receptors in prostacyclin sensing by lung fibroblasts. Am J Respir Cell Mol Biol 2006; 34: 242–246.
Nikitopoulou I, Manitsopoulos N, Kotanidou A, et al. Orotracheal treprostinil administration attenuates bleomycin-induced lung injury, vascular remodeling, and fibrosis in mice. Pulm Circ 2019; 9: 2045894019881954.
Waxman A, Restrepo-Jaramillo R, Thenappan T, et al. Inhaled treprostinil in pulmonary hypertension due to interstitial lung disease. N Engl J Med 2021; 384: 325–334.
Nathan SD, Waxman A, Rajagopal S, et al. Inhaled treprostinil and forced vital capacity in patients with interstitial lung disease and associated pulmonary hypertension: a post-hoc analysis of the INCREASE study. Lancet Respir Med 2021; 9: 1266–1274.
Effendi WI, Nagano T. The Hedgehog signaling pathway in idiopathic pulmonary fibrosis: resurrection time. Int J Mol Sci 2021; 23: 171.
Maher TM, Goldin JG, DiFrancesco A, et al. ENV-101, a novel hedgehog inhibitor, increases lung function, and reduces lung fibrosis in patients with idiopathic pulmonary fibrosis: results from a randomized, double-blind, placebo-controlled phase 2 trial. Am J Respir Crit Care Med 2024; 209: A1056.
Shen G, Zheng F, Ren D, et al. Anlotinib: a novel multi-targeting tyrosine kinase inhibitor in clinical development. J Hematol Oncol 2018; 11: 120.
Ruan H, Lv Z, Liu S, et al. Anlotinib attenuated bleomycin-induced pulmonary fibrosis via the TGF-β1 signalling pathway. J Pharm Pharmacol 2020; 72: 44–55.
Young ON, Bourke JE, Widdop RE. Catch your breath: The protective role of the angiotensin AT2 receptor for the treatment of idiopathic pulmonary fibrosis. Biochem Pharmacol 2023; 217: 115839.
Ganslandt C, Maher TM, Molyneaux PL, et al. Buloxibutid, a novel angiotensin ii type 2 receptor agonist, stabilized and improved lung function in individuals with idiopathic pulmonary fibrosis in the 36-week phase 2 AIR trial. Am J Respir Crit Care Med 2024; 209: A1055.
Johnson SR, Bernstein EJ, Bolster MB, et al. 2023 American College of Rheumatology (ACR)/American College of Chest Physicians (CHEST) guideline for the treatment of interstitial lung disease in people with systemic autoimmune rheumatic diseases. Arthritis Rheumatol 2024; 76: 1182–1200.
Khanna D, Albera C, Fischer A, et al. An open-label, phase II study of the safety and tolerability of pirfenidone in patients with scleroderma-associated interstitial lung disease: the LOTUSS trial. J Rheumatol 2016; 43: 1672–1679.
Khanna D, Spino C, Bernstein E, et al. Combination therapy of mycophenolate mofetil and pirfenidone vs. mycophenolate alone: results from the Scleroderma Lung Study III [abstract]. Arthritis Rheumatol 2022; 74: Suppl. 9, 0520.
Gordon JK, Martyanov V, Franks JM, et al. Belimumab for the treatment of early diffuse systemic sclerosis: results of a randomized, double-blind, placebo-controlled, pilot trial. Arthritis Rheumatol 2018; 70: 308–316.
Siefker D, Xu Z, Ferrer M, et al. Efzofitimod: a novel therapeutic candidate for SSc-ILD. Eur Respir J 2023; 62: Suppl. 67, PA419.
Myasoedova E, Matteson EL. Updates on interstitial lung disease and other selected extra-articular manifestations of rheumatoid arthritis. Curr Opin Rheumatol 2024; 36: 203–208.
Guiot J, Miedema J, Cordeiro A, et al. Practical guidance for the early recognition and follow-up of patients with connective tissue disease-related interstitial lung disease. Autoimmun Rev 2024; 23: 103582.
Juge PA, Granger B, Debray MP, et al. A risk score to detect subclinical rheumatoid arthritis-associated interstitial lung disease. Arthritis Rheumatol 2022; 74: 1755–1765.
Solomon JJ, Danoff SK, Woodhead FA, et al.. Safety, tolerability, and efficacy of pirfenidone in patients with rheumatoid arthritis-associated interstitial lung disease: a randomised, double-blind, placebo-controlled, phase 2 study. Lancet Respir Med 2023; 11: 87–96..
Karampitsakos T, Tzilas V, Papaioannou O, et al. Clinical features and outcomes of patients with myositis associated-interstitial lung disease. Front Med 2022; 9: 1096203.
Morisset J, Johnson C, Rich E, et al. Management of myositis-related interstitial lung disease. Chest 2016; 150: 1118–1128.
Bączek K, Piotrowski WJ. Lung fibrosis in sarcoidosis. Is there a place for antifibrotics? Front Pharmacol 2024; 15: 1445923.
Bonham CA, Strek ME, Patterson KC. From granuloma to fibrosis: sarcoidosis associated pulmonary fibrosis. Curr Opin Pulm Med 2016; 22: 484–491.
Obi ON, Baughman RP, Crouser ED, et al. Therapeutic doses of efzofitimod demonstrate efficacy in pulmonary sarcoidosis. ERJ Open Res 2025; 11: 00536-2024.
Yang S, Liu P, Jiang Y, et al. Therapeutic applications of mesenchymal stem cells in idiopathic pulmonary fibrosis. Front Cell Dev Biol 2021; 9: 639657.
Ruan P, Todd JL, Zhao H, et al. Integrative multi-omics analysis reveals novel idiopathic pulmonary fibrosis endotypes associated with disease progression. Respir Res 2023; 24: 141.
Hussen BM, Najmadden ZB, Abdullah SR, et al. CRISPR/Cas9 gene editing: a novel strategy for fighting drug resistance in respiratory disorders. Cell Commun Signal 2024; 22: 329.
Karampitsakos T, Galaris A, Chrysikos S, et al. Expression of PD-1/PD-L1 axis in mediastinal lymph nodes and lung tissue of human and experimental lung fibrosis indicates a potential therapeutic target for idiopathic pulmonary fibrosis. Respir Res 2023; 24: 279.
Karampitsakos T, Juan-Guardela BM, Tzouvelekis A, et al. Precision medicine advances in idiopathic pulmonary fibrosis. EBioMedicine 2023; 95: 104766.
